|
1
|
Holohan C, van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Driscoll L and Clynes M: Biomarkers and
multiple drug resistance in breast cancer. Curr Cancer Drug
Targets. 6:365–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ellis LM and Hicklin DJ: Resistance to
targeted therapies: Refining anticancer therapy in the era of
molecular oncology. Clin Cancer Res. 15:7471–7478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambi G and Ferlini C: Role of microRNAs in drug resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan H, Guo J and Su Z: Advances in
understanding the interrelations between leptin resistance and
obesity. Physiol Behav. 130:157–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wallace AM, McMahon AD, Packard CJ, Kelly
A, Shepherd J, Gaw A and Sattar N: Plasma leptin and the risk of
cardiovascular disease in the west of Scotland coronary prevention
study (WOSCOPS). Circulation. 104:3052–3056. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Polyzos SA, Aronis KN, Kountouras J,
Raptis DD, Vasiloglou MF and Mantzoros CS: Circulating leptin in
non-alcoholic fatty liver disease: A systematic review and
meta-analysis. Diabetologia. 59:30–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stolzenberg-Solomon RZ, Newton CC,
Silverman DT, Pollak M, Nogueira LM, Weinstein SJ, Albanes D,
Männistö S and Jacobs EJ: Circulating leptin and risk of pancreatic
cancer: A pooled analysis from 3 cohorts. Am J Epidemiol.
182:187–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andò S, Barone I, Giordano C, Bonofiglio D
and Catalano S: The multifaceted mechanism of leptin signaling
within tumor microenvironment in driving breast cancer growth and
progression. Front Oncol. 4:3402014.PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nagaraj AB, Joseph P, Kovalenko O, Singh
S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S and
DiFeo A: Critical role of Wnt/β-catenin signaling in driving
epithelial ovarian cancer platinum resistance. Oncotarget.
6:23720–23734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang G, Zhu H, Shi Y, Wu W, Cai H and
Chen X: cir-ITCH plays an inhibitory role in colorectal cancer by
regulating the Wnt/β-catenin pathway. PLoS One. 10:e01312252015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friedman JM and Halaas JL: Leptin and the
regulation of body weight in mammals. Nature. 395:763–770. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Howard JM, Cathcart MC, Healy L, Beddy P,
Muldoon C, Pidgeon GP and Reynolds JV: Leptin and adiponectin
receptor expression in oesophageal cancer. Br J Surg. 101:643–652.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bain GH, Collie-Duguid E, Murray GI,
Gilbert FJ, Denison A, McKiddie F, Ahearn T, Fleming I, Leeds J,
Phull P, et al: Tumour expression of leptin is associated with
chemotherapy resistance and therapy-independent prognosis in
gastro-oesophageal adenocarcinomas. Br J Cancer. 110:1525–1534.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY,
Park BE, Jang Y, Cho SY and Kim HS: Potential role of leptin in
angiogenesis: Leptin induces endothelial cell proliferation and
expression of matrix metalloproteinases in vivo and in vitro. Exp
Mol Med. 33:95–102. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ding Y, Cao Y, Wang B, Wang L, Zhang Y,
Zhang D, Chen X, Li M and Wang C: APPL1-mediating leptin signaling
contributes to proliferation and migration of cancer cells. PLoS
One. 11:e01661722016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McGlothen TZ, Hogan-Blaylock D, Gillespie
C, Colbert L, Guo G, Sanford G and Gonzalez-Perez RR:
Leptin-Notch-Wnt axis affects drug resistance in breast cancer.
Cancer Res. 72:2012. View Article : Google Scholar
|
|
21
|
Somasundar P, Frankenberry KA, Skinner H,
Vedula G, McFadden DW, Riggs D, Jackson B, Vangilder R, Hileman SM
and Vona-Davis LC: Prostate cancer cell proliferation is influenced
by leptin. J Surg Res. 118:71–82. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang D, Chen J, Chen H, Duan Z, Xu Q, Wei
M, Wang L and Zhong M: Leptin regulates proliferation and apoptosis
of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J
Biosci. 37:91–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teng Y, Wang X, Wang Y and Ma D:
Wnt/beta-catenin signaling regulates cancer stem cells in lung
cancer A549 cells. Biochem Biophys Res Commun. 392:373–379. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khramtsov AI, Khramtsova GF, Tretiakova M,
Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation
is enriched in basal-like breast cancers and predicts poor outcome.
Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
King TD, Suto MJ and Li Y: The
Wnt/β-catenin signaling pathway: A potential therapeutic target in
the treatment of triple negative breast cancer. J Cell Biochem.
113:13–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
